On April 8, 2020, nine departments — the Department of Science and Technology, the Development and Reform Commission, the Department of Industry and Information Technology, the Department of Finance, the Health Commission, the Healthcare Security Administration, the Local Financial Supervision and Administration Bureau, the Traditional Chinese Medicine Bureau, and the Drug Administration of Guangdong Province — jointly issued the Several Policy Measures on Promoting Innovative Development of Biopharmaceuticals (hereinafter the "Measures"), with the aim of enhancing original innovation capacity and international competitiveness in biopharmaceuticals, promoting high-quality development of biopharmaceutical science, technology, and industry, and improving biosecurity governance capacity.
As a high-tech innovation hub, Shenzhen has long been at the national forefront in biopharmaceutical development. On March 3 of this year, the Shenzhen Municipal Government issued the Guiding Opinions on Promoting the Clustered Development of the Biopharmaceutical Industry in Shenzhen and two supporting documents, as well as the Several Measures on Promoting the Clustered Development of the Biopharmaceutical Industry in Shenzhen. These documents explicitly mention developing biotherapy technologies such as stem cell therapy, immunotherapy, and gene therapy, and actively promoting the translation of research achievements and supporting the establishment of clinical research and translational application platforms for somatic cell therapy.
Cell therapy technology will be one of the most important means for treating human disease in the future. Formal channels for filings of stem cell new drug research and clinical research are now also open. As a leader in the cell industry, Beike Biotech has consistently regarded technological innovation and quality as the core and lifeline of the company. The company is committed to driving the high-quality development of the domestic cell industry through the synchronized promotion of R&D and standardization, enhancing China's initiative and voice within the international cell industry, and applying cell research achievements to the treatment of major diseases as soon as possible. In 2019, Beike Biotech's research achievement "Key Technology Innovation and Clinical Application of Allogeneic Mesenchymal Stem Cells in the Treatment of Refractory Lupus Erythematosus" received the National Technology Invention Award. In 2020, in the fight against the COVID-19 pandemic, the project "Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Coronavirus-Induced Severe Pneumonia", jointly submitted by Beike Biotech and the Third People's Hospital of Shenzhen, was approved by the Guangdong Provincial Department of Science and Technology under the 2020 Guangdong Emergency Special Project for Scientific and Technological Research on the Prevention and Control of Novel Coronavirus.
